乐观
$23.17
情景价格
$10.940
-0.100 (-0.91%)收盘时
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Phreesia VP Michael Rasbury Named Rising Star in Healthcare

Phreesia Named to TIME's World’s Top HealthTech Companies for Second Year

Phreesia Partners with DeepIntent to Enhance Healthcare Marketing

Phreesia Stock Plummets Following Analyst Downgrade

Phreesia Stock Downgraded Following Earnings Miss
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).
Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。